Annual report pursuant to Section 13 and 15(d)

12. Commitments and Contingencies (Details Narrative)

v2.4.0.8
12. Commitments and Contingencies (Details Narrative) (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Rent expense $ 413 $ 392
Potential severance 1,130  
Aggregated annual salaries 935  
Innovacyn
   
Accounts receivable 220 264
AmDerma
   
Deferred revenue 250  
Revenue earned   250
More Pharma
   
Accounts receivable 790 580
Amortization of transaction fees 1,501 932
Transaction costs $ 63 $ 39